MINNEAPOLIS - May 1, 2013 - Medtronic, Inc. (NYSE: MDT) announced today it has entered into an innovative partnership with the National Institute of Hospital Administration, an important think tank under China's National Health and Family Planning Commission, to carry out a series of research projects focusing on building an integrated care pathway for patients with Type 1 diabetes. This effort is an example of a partnership focused on working with an important organization to access data that can be used to understand the economic and clinical value of therapies and how they can be best utilized in a patient population.

Both Medtronic and the National Institute of Hospital Administration will participate in establishing pilot sites for the proposed domestic Type 1 diabetes integrated pathway system at 10-12 regional children's hospitals and general hospitals across the country. The goal is to gather insight that can support the foundation of a Chinese nationwide system to improve the treatment of Type 1 diabetes patients and reduce the likelihood of complications among this vulnerable population.

"Type 1 diabetes is a disease of long course, which demands sophisticated treatment and care both in and outside the hospitals. Type 1 diabetes patients are more susceptible to serious complications compared to Type-2 diabetes sufferers, often leading to huge financial burdens for patients' families and the society as a whole," said Liang Huiming, the director of The MOH National Institute of Hospital Administration. "To control the consequence and alleviate the impact of this disease, we need a systematic social engineering approach, which involves efforts from medical professionals, government agencies, communities and patient families. We are hopeful that this initiative will lay the foundation for a Type 1 diabetes integrated care pathway. If successful, this initiative could even potentially set the goalposts for future chronic disease management efforts in China," Liang said.

Chris Lee, the President of Medtronic Greater China said: "As one of the world's leading medical technology companies, Medtronic has a strong commitment to bring broader benefits to patients and society on top of offering cutting-edge products. In this joint endeavor to help China prepare a nationwide Type 1 diabetes integrated pathway, we will share with the Chinese government the extensive experience we have accumulated through dealing with similar mechanism in other countries around the world. This is the advantage of being a multinational medical technology company and part of our global objective to bring clinical effectiveness and value around the world."

About Medtronic
Medtronic, Inc. (www.medtronic.com), headquartered in Minneapolis, is the global leader in medical technology - alleviating pain, restoring health and extending life for millions of people around the world.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

-end-

Contacts:
Cindy Resman
Public Relations
+1-763-505-0291

Jeff Warren
Investor Relations
+1-763-505-2696